for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fresenius Medical Care AG & Co. KGaA

FMEG.DE

Latest Trade

73.26EUR

Change

-0.80(-1.08%)

Volume

639,066

Today's Range

72.72

 - 

74.00

52 Week Range

53.50

 - 

81.10

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
74.06
Open
73.74
Volume
639,066
3M AVG Volume
17.67
Today's High
74.00
Today's Low
72.72
52 Week High
81.10
52 Week Low
53.50
Shares Out (MIL)
293.51
Market Cap (MIL)
22,559.27
Forward P/E
17.09
Dividend (Yield %)
1.62

Next Event

Q2 2020 Fresenius Medical Care AG & Co KGaA Earnings Release

Latest Developments

More

Fresenius Medical Care Holds Virtual General Meeting On August 27, 2020

FMC Expands Production At St. Wendel Plant In Response To Higher Demand Caused By COVID-19 Pandemic

Fresenius Medical Care Places Bonds With A Volume Of 1.25 Bln Eur

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.

Industry

Healthcare Facilities

Contact Info

Else-Kroener-Strasse 1

61352

Germany

+49.6172.6090

https://www.freseniusmedicalcare.com/

Executive Leadership

Dieter Schenk

Chairman of the Supervisory Board

Rice Powell

Chairman of the Management Board, Chief Executive Officer

Ben J. Lipps

Honorary Chairman

Rolf A. Classon

Independent Vice Chairman of the Supervisory Board

Helen Giza

Chief Financial Officer, Member of the Management Board

Key Stats

1.92 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

17.8K

2018

16.5K

2019

17.5K

2020(E)

18.5K
EPS (EUR)

2017

4.170

2018

4.490

2019

4.520

2020(E)

4.364
Price To Earnings (TTM)
18.36
Price To Sales (TTM)
1.27
Price To Book (MRQ)
1.81
Price To Cash Flow (TTM)
7.29
Total Debt To Equity (MRQ)
121.51
LT Debt To Equity (MRQ)
82.84
Return on Investment (TTM)
6.09
Return on Equity (TTM)
4.40

Latest News

Latest News

BRIEF-Fresenius Medical Care Holds Virtual General Meeting On August 27, 2020

* FRESENIUS MEDICAL CARE HOLDS VIRTUAL GENERAL MEETING ON AUGUST 27, 2020 - DIVIDEND PROPOSAL UNCHANGED

BRIEF-FMC Expands Production At St. Wendel Plant In Response To Higher Demand Caused By COVID-19 Pandemic

* EXPANDS PRODUCTION AT ST. WENDEL PLANT IN RESPONSE TO HIGHER DEMAND CAUSED BY COVID-19 PANDEMIC

Germany's Fresenius Medical Care confirms data leak in Serbia after hacker attack

German dialysis provider Fresenius Medical Care (FMC) <FMEG.DE> confirmed on Thursday that patient data from some of its dialysis centres in Serbia leaked after a recent hacker attack.

BRIEF-Fresenius Medical Care Places Bonds With A Volume Of 1.25 Bln Eur

* SAYS PLACED BONDS WITH A TOTAL VOLUME OF 1.25 BILLION EUROS

Fresenius reports Q1 net income beat on pandemic demand

Healthcare group Fresenius <FREG.DE> beat first-quarter net income expectations on Wednesday, citing a U.S. and European spike in demand for drugs and devices for COVID-19 patients and government help with costs incurred by health providers.

Fresenius Medical Care reports first-quarter beat, cites strong underlying business

German dialysis specialist Fresenius Medical Care <FMEG.DE> beat first-quarter net income expectations on Wednesday, saying its strong underlying business offset costs related to the coronavirus pandemic.

BRIEF-Fresenius Medical Care Confirms 2020 Financial Targets

* POSITIVE EARNINGS GROWTH DESPITE NEGATIVE IMPACT FROM COVID-19

BRIEF-Fresenius says it will increase supply of essential drugs

* FRESENIUS KABI TAKES COMPREHENSIVE MEASURES TO INCREASE SUPPLY OF ESSENTIAL DRUGS DURING COVID-19 PANDEMIC

Fresenius Medical Care working with dialysis providers in U.S. to tackle coronavirus

Fresenius Medical Care (FMC) on Wednesday said it was working with other dialysis providers to provide care in isolation for people with kidney problems in the United States who are or may be infected with coronavirus.

BRIEF-Fresenius Medical Care Postpones 2020 Annual General Meeting

* POSTPONES ITS 2020 ANNUAL GENERAL MEETING, WHICH WAS SCHEDULED FOR MAY 19, TO A LATER DATE THIS YEAR DUE TO CORONAVIRUS PANDEMIC

REFILE-BRIEF-Fresenius: FDA Approves Fresenius Medical Care's Novalung

* US FOOD AND DRUG ADMINISTRATION APPROVES FRESENIUS MEDICAL CARE FOR NOVALUNG FOR THE TREATMENT OF ACUTE LUNG AND CARDIOPULMONARY FAILURE

Fresenius forecasts 2020 profit growth driven by drug, dialysis units

German healthcare group Fresenius <FREG.DE> said it expects net income to increase in 2020 after strong growth in its dialysis business, and in its infusion drugs unit in emerging markets, helped it to just beat fourth quarter expectations.

FMC sees U.S. government easing home dialysis goals

Fresenius Medical Care (FMC) , the world's largest kidney dialysis provider, is confident the U.S. government will soften initial targets for treating patients with kidney disease at home rather than in dedicated centres.

Fresenius Medical says fourth-quarter operating profit up 3%

Germany's Fresenius Medical Care <FMEG.DE> on Wednesday said quarterly adjusted operating income edged 3% higher as growth in dialysis services and products was partly offset by a negative adjustment for accounts receivable in a legal dispute in North America.

Fresenius Medical says Q4 operating profit up 3%

Germany's Fresenius Medical Care on Wednesday said quarterly adjusted operating income edged 3% higher as growth in dialysis services and products was partly offset by a negative adjustment for accounts receivable in a legal dispute in North America.

Fresenius beats third-quarter forecasts with strong sales of home dialysis treatments

German healthcare group Fresenius <FREG.DE> beat third-quarter revenue forecasts on Tuesday, citing a solid performance by its infusion drugs unit in emerging markets and strong growth in home treatment at its separately listed dialysis business.

Fresenius Medical Care reports Q3 beat on record home dialysis in North America

German dialysis specialist Fresenius Medical Care reported on Tuesday a 9% rise in its third-quarter revenue, citing record growth in home dialysis in North America.

Fresenius Medical Care appoints Takeda executive Helen Giza as CFO

German dialysis specialist Fresenius Medical Care <FMEG.DE> has hired Helen Giza from Japan's Takeda Pharmaceutical <4502.T> as its new finance chief, replacing Mike Brosnan.

Fresenius slides as weakness in dialysis unit offsets improved outlook

Shares in German healthcare group Fresenius <FREG.DE> slid on Tuesday after its dialysis unit FMC reported smaller than expected cost savings and said full-year earnings growth would likely come in at the lower end of guidance.

Fresenius Medical Care confirms 2019 targets

German dialysis specialist Fresenius Medical Care <FMEG.DE> reported on Tuesday a 3% rise in its second-quarter revenue, citing healthy growth in its U.S. dialysis business.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up